Warning: The NCBI web site requires JavaScript to function. more...

PubMed

US National Library of Medicine National Institutes of Health

Create RSS
RSS Settings
- Search: Parrish KE[au]
- Number of items displayed:
- Feed name:
Create alert
Advanced
Help

Search results

Items: 14

Select item 300033441.

Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine.

Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN, Elmquist WF.

Pharm Res. 2018 Jul 12;35(9):177. doi: 10.1007/s11095-018-2455-9. Review.

PMID:: 30003344

Similar articles

Select item 299704802.

Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood-brain barrier.

Kim M, Ma DJ, Calligaris D, Zhang S, Feathers RW, Vaubel RA, Meaux I, Mladek AC, Parrish KE, Jin F, Barriere C, Debussche L, Watters J, Tian S, Decker PA, Eckel-Passow JE, Kitange GJ, Johnson AJ, Parney IF, Anastasiadis PZ, Agar NYR, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2018 Jul 3. pii: molcanther.0600.2017. doi: 10.1158/1535-7163.MCT-17-0600. [Epub ahead of print]

PMID:: 29970480

Similar articles

Select item 294404503.

Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier.

Laramy JK, Kim M, Parrish KE, Sarkaria JN, Elmquist WF.

J Pharmacol Exp Ther. 2018 May;365(2):249-261. doi: 10.1124/jpet.117.246116. Epub 2018 Feb 12.

PMID:: 29440450

Similar articles

Select item 289475024.

Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.

Kizilbash SH, Gupta SK, Chang K, Kawashima R, Parrish KE, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Kitange GJ, Shen Y, Feng Y, Protter AA, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2017 Dec;16(12):2735-2746. doi: 10.1158/1535-7163.MCT-17-0365. Epub 2017 Sep 25.

PMID:: 28947502

Similar articles

Select item 288479175.

Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma.

Laramy JK, Kim M, Gupta SK, Parrish KE, Zhang S, Bakken KK, Carlson BL, Mladek AC, Ma DJ, Sarkaria JN, Elmquist WF.

J Pharmacol Exp Ther. 2017 Nov;363(2):136-147. doi: 10.1124/jpet.117.243477. Epub 2017 Aug 28.

PMID:: 28847917

Similar articles

Select item 285469176.

Challenges in the delivery of therapies to melanoma brain metastases.

Gampa G, Vaidhyanathan S, Resman BW, Parrish KE, Markovic SN, Sarkaria JN, Elmquist WF.

Curr Pharmacol Rep. 2016 Dec;2(6):309-325. doi: 10.1007/s40495-016-0072-z. Epub 2016 Nov 9.

PMID:: 28546917

Free PMC Article

Similar articles

Select item 268832717.

ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model.

Mittapalli RK, Chung AH, Parrish KE, Crabtree D, Halvorson KG, Hu G, Elmquist WF, Becher OJ.

Mol Cancer Ther. 2016 May;15(5):819-29. doi: 10.1158/1535-7163.MCT-15-0093. Epub 2016 Feb 16.

PMID:: 26883271

Free PMC Article

Similar articles

Select item 266374998.

In vitro and in vivo characterization of CYP inhibition by 1-aminobenzotriazole in rats.

Parrish KE, Mao J, Chen J, Jaochico A, Ly J, Ho Q, Mukadam S, Wright M.

Biopharm Drug Dispos. 2016 May;37(4):200-11. doi: 10.1002/bdd.2000.

PMID:: 26637499

Similar articles

Select item 266042459.

Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases.

Vaidhyanathan S, Wilken-Resman B, Ma DJ, Parrish KE, Mittapalli RK, Carlson BL, Sarkaria JN, Elmquist WF.

J Pharmacol Exp Ther. 2016 Feb;356(2):251-9. doi: 10.1124/jpet.115.229393. Epub 2015 Nov 24.

PMID:: 26604245

Free PMC Article

Similar articles

Select item 2643815710.

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.

Parrish KE, Cen L, Murray J, Calligaris D, Kizilbash S, Mittapalli RK, Carlson BL, Schroeder MA, Sludden J, Boddy AV, Agar NY, Curtin NJ, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2015 Dec;14(12):2735-43. doi: 10.1158/1535-7163.MCT-15-0553. Epub 2015 Oct 5.